Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
You may also be interested in...
Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.
BMS/Celgene and AbbVie/Allergan were the biggest biopharma deals by dollar value in 2019, and the third and seventh largest ever. The year saw 23 deals valued at $1bn or more, including 20 M&A agreements.
With rebate reform efforts stalled, insulin manufacturer broadens efforts to lower prices through authorized generics, but PBMs may still like the big rebates they can get on the original brands.